Progress in Diagnostics and Therapy of Prostatic Cancer

Progress in Diagnostics and Therapy of Prostatic Cancer

This book takes into account that only an international exchange of new findings can create the necessary conditions for improved treatment.

Author: W.B. Peeling

Publisher: Springer Science & Business Media

ISBN: 9783642799471

Category: Medical

Page: 79

View: 810

There is now increasing awareness by the general public in European countries that prostate cancer is a serious threat to health, and this has created higher expectations for improved and more effective methods for detecting and treating the disease. However, urologists are very conscious of the limitations of the diagnostic methods that are available and are even more concerned about the apparent lack of therapeutic advances made during the past 50 years since Huggins discovered the fundamental principles of endocrine treatment for is theo prostate cancer. Recent efforts to detect the disease when it retically "curable" have been successful, certainly in the USA, but this has highlighted our uncertainty about the best treatment for early stage prostate cancer, and there is no doubt that radical pro statectomy is sometimes carried out on men who may not be threa tened by their illness. While it is generally accepted that many men with prostate cancer will die of old age rather than this malignancy, it cannot be ignored that this disease kills many others in a process that is frequently lingering, miserable, and humiliating, not only for the victim but also his family. There are many important issues about prostate cancer that remain unclear at the present time, some of which are addressed by the reviews in this book. The debate about early detection and screening can arouse considerable heat in otherwise placid urological mee tings.
Categories: Medical

Surviving That Prostate Cancer

Surviving That Prostate Cancer

This book makes it easy. This guide covers every aspect of prostate cancer, from potential causes including diet to tests for diagnosis, curative treatment, and innovative means of controlling advanced stages of cancer.

Author: Howard V Silva

Publisher: Independently Published

ISBN: 9798372729186

Category:

Page: 0

View: 434

Choosing the right prostate cancer treatment can be a daunting task. This book makes it easy. This guide covers every aspect of prostate cancer, from potential causes including diet to tests for diagnosis, curative treatment, and innovative means of controlling advanced stages of cancer.
Categories:

Dx Rx Prostate Cancer

Dx Rx  Prostate Cancer

Important Notice: The digital edition of this book is missing some of the images or content found in the physical edition.

Author: Lewis J. Kampel

Publisher: Jones & Bartlett Publishers

ISBN: 9781449686956

Category: Medical

Page: 280

View: 102

Dx/Rx: Prostate Cancer, Second Edition is a thoroughly revised and updated pocket-sized manual that details precise, up-to-date information for diagnosis and treatment of Prostate Cancer. Throughout the book, tables and figures summarize important clinical data and current professional society recommendations, while salient references direct readers to additional information. Updates have been made to the Second Edition, including additional information on treatment options for both early and advanced prostate cancer, an improved staging section, including representative scans as well as new information on complications and para-neoplastic syndromes. Dx/Rx: Prostate Cancer features current, quick and concise information and is a must-have resource for instant access on the ward or in the clinic. Important Notice: The digital edition of this book is missing some of the images or content found in the physical edition.
Categories: Medical

Prostate Cancer Treatment Based on the Suppression of Angiogenesis and Metastasis

Prostate Cancer Treatment Based on the Suppression of Angiogenesis and Metastasis

We have developed a polymer made from the cell adhesion protein fibronectin (termed superfibronectin, sFN). We have previously reported that sFN has anti-metastatic effects against multiple tumor types, including human prostate cancer.

Author:

Publisher:

ISBN: OCLC:946633654

Category:

Page: 16

View: 974

Although curative treatments are available for organ-confined prostate cancer, the metastatic spread to organs such as the lymph nodes and bone results in an incurable disease, despite the effectiveness of initial hormone therapy. We have developed a polymer made from the cell adhesion protein fibronectin (termed superfibronectin, sFN). We have previously reported that sFN has anti-metastatic effects against multiple tumor types, including human prostate cancer. We propose here to study the antiangiogenic and antimetastatic effects of sFN and of the III1C fragment in vivo using prostate cancer transgenic and other experimental models. We will use a transgenic mouse model of prostate cancer (TRAMP mice) to test the therapeutic effects of sFN. We aim to demonstrate that the combination of the anti-tumorigenesis, anti-metastatic and anti-angiogenic properties of sFN makes it a unique and powerful biological agent against prostate cancer. If our expectations are realized, we will proceed with clinical trials in prostate cancer patients.
Categories:

Dr Patrick Walsh s Guide to Surviving Prostate Cancer

Dr  Patrick Walsh s Guide to Surviving Prostate Cancer

This guide covers every aspect of prostate cancer, from potential causes including diet to tests for diagnosis, curative treatment, and innovative means of controlling advanced stages of cancer.

Author: Patrick C. Walsh

Publisher: Hachette UK

ISBN: 9781538763636

Category: Health & Fitness

Page: 480

View: 172

This guide covers every aspect of prostate cancer, from potential causes including diet to tests for diagnosis, curative treatment, and innovative means of controlling advanced stages of cancer.
Categories: Health & Fitness

The Role of Kr ppel like Factor 6 splice Variant 1 and C MYC in the Development and Progression of Prostate Cancer

The Role of Kr  ppel like Factor 6 splice Variant 1 and C MYC in the Development and Progression of Prostate Cancer

Understanding the genetic drivers of disease progression is critical for the development of novel targeted therapies and markers that will predict the biological behavior of a given tumor such that indolent disease is not over-treated and ...

Author: Sudeh Izadmehr

Publisher:

ISBN: OCLC:1028580112

Category:

Page: 148

View: 955

Cancers harbor multiple genetic alterations that contribute to tumorigenesis by disrupting the normal function of proto-oncogenes and tumor suppressor genes. Prostate cancer is a heterogeneous and genetically complex disease. An incomplete understanding of how prostate cancer, the most common neoplasia in men, transitions from localized adenocarcinoma to disseminated disease has challenged effective clinical management. Currently, curative treatments are not available for advanced prostate cancer, and prognostic biomarkers to estimate the likelihood of prostate cancer aggressiveness are lacking. Understanding the genetic drivers of disease progression is critical for the development of novel targeted therapies and markers that will predict the biological behavior of a given tumor such that indolent disease is not over-treated and aggressive forms receive adequate treatment. Prior studies have uncovered c-MYC dysregulation to be a frequent event in human prostate cancer pathogenesis; c-MYC is sufficient to initiate prostatic intraepithelial neoplasia (PIN) resulting in self-limited and indolent prostate adenocarcinoma. A second hit may be necessary and sufficient to advance c-MYC-driven prostate cancer to a metastatic state. Krüppel-like factor 6-splice variant 1 (KLF6-SV1) is a late progression event in prostate tumorigenesis by promoting invasive and metastatic disease. To define KLF6-SV1's functional role as a promoter of c-MYC-driven prostate adenocarcinoma, a novel double transgenic mouse model, MYC-SV1, expressing human KLF6-SV1 and c-MYC genes was created. Mice reliably developed murine prostate intraepithelial neoplasia followed by invasive prostate adenocarcinoma and metastases; the phases of prostate cancer development and progression with phenotypic and molecular features of aggressive, late-stage human disease. A second mouse model, a syngeneic MYC-SV1 mouse model, CS3, also developed highly invasive and metastatic tumors. Increased proliferation, invasion, tumor-initiated vascular growth and dedifferentiation were observed in MYC-SV1 and CS3 tumors. c-MYC was required for KLF6-SV1/ c-MYC tumor maintenance. Inhibition of c-MYC through castration reduced tumor burden. The expression of KLF6-SV1 and c-MYC were significantly correlated at both the mRNA and protein levels in human prostate biospecimens. The co-expression of human c-MYC and KLF6-SV1 resulted in functional and biological synergy in mice and humans. Our studies underscore the functional significance of KLF6-SV1 in c-MYC-driven prostate adenocarcinoma, establishing KLF6-SV1 as a key regulator of c-MYC -driven adenocarcinoma and a target for therapeutic intervention. These findings further underscore the importance of using mouse models that fully recapitulate the entire spectrum of disease development to examine the gene function and molecular basis of metastatic transformation. Our findings provide a new and clinically relevant transgenic and syngeneic mouse model of prostate cancer, improve our understanding of genetic drivers of lethal prostate cancer, and identify promising new therapeutic targets for metastatic disease.
Categories:

Prostate Cancer Diagnostic and Therapeutic Advances

Prostate Cancer   Diagnostic and Therapeutic Advances

2.1 Chemotherapeutic agents Chemotherapy is often used as a main regimen in the overall treatment of most cancers. ... Lack of curative treatments at the advanced prostate cancer, underline the importance of additional trials for the ...

Author:

Publisher: Inst za onkologiju i radiol

ISBN: 9789533073194

Category:

Page: 391

View: 878

Categories:

Induced Expression of Androgen Receptor in Androgen Independent Prostate Cancer Cells Using an IkBalpha Super Repressor

Induced Expression of Androgen Receptor in Androgen Independent Prostate Cancer Cells Using an IkBalpha Super Repressor

Thus, we now are poised to evaluate these novel insights of androgen interactions in vivo, a critical step toward designing novel therapeutic strategies.

Author:

Publisher:

ISBN: OCLC:74265586

Category:

Page: 23

View: 345

Advanced prostate cancer continues to kill 29,000 men annually in the United States. Despite strides in obtaining extended remissions through the use of hormones and chemotherapeutic agents, there is still no curative therapy for this devastating disease. While most prostate cancers are responsive to androgens and while androgen withdrawal is the main form of treatment, the failure of primary hormone therapy is attributed to androgen-independent tumor expansion. Mechanisms for the transition from androgen-sensitive to androgen-refractory disease are currently not well understood. We proposed to investigate the role of TNF-alpha-mediated NF-icB signaling in androgen-sensitive and -insensitive prostate cancer, as many androgen-independent prostate cancer cell lines exhibit resistance to this pathway and as TNF-alpha is detected at high serum levels in relapsing prostate cancer patients compared to those in remission or untreated. We subsequently demonstrated activation of TNF-alpha-induced apoptosis with an IkB-alpha super repressor and relieved NF-KB repression of the androgen receptor in androgen-independent prostate cancer cell lines cells. During this current funding period we report generation of a non-invasive quantitative murine model for metastatic prostate cancer. Thus, we now are poised to evaluate these novel insights of androgen interactions in vivo, a critical step toward designing novel therapeutic strategies.
Categories:

Management of Advanced Prostate Cancer

Management of Advanced Prostate Cancer

Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67(5):852–63. 2. Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, ...

Author: Choung Soo Kim

Publisher: Springer

ISBN: 9789811069437

Category: Medical

Page: 201

View: 107

This textbook summarizes the state of the art in the management of locally advanced and metastatic prostate cancer with the aim of providing the knowledge required for optimal treatment decision making in individual cases. Readers will find comprehensive coverage of the latest developments in surgery, radiotherapy, androgen deprivation therapy (ADT), chemotherapy, and immunotherapy. The role of the hormonal therapies abiraterone and enzalutamide and docetaxel-based chemotherapy in castration-resistant prostate cancer and hormone-sensitive metastatic disease is carefully evaluated. Among the other therapies discussed are LHRH agonists and antagonists, cabazitaxel, radium-223, and various novel agents still under clinical trials. The section on surgical approaches addresses, among other topics, the use of robot-assisted radical prostatectomy, pelvic lymphadenectomy, and the benefits of adjuvant and neoadjuvant therapy. The current role of external beam radiotherapy, alone or in combination with ADT and brachytherapy, for locally advanced disease is reviewed. Management of Advanced Prostate Cancer will be a valuable resource for practitioners at all levels of expertise.
Categories: Medical